Frontlight ResearchEarly access
Not yet recruitingPhase 1/2
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
Key facts
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 10 people, planned
- Starts
- 30 Jun 2027
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Treatments tested
- Direct intravenous injection of ivlv-X1 lentiviral vector
- Record updated
- 3 November 2026
Who can take part
- Age
- 1 month to 1 year
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Diagnosis of SCID-X1 based on:; A proven mutation in the common interleukin-2 receptor gamma chain gene as defined by direct sequencing of patient DNA; T-cell immune deficiency defined as one or more of the following: CD3+ autologous T cells < 300/ul, or less than 50% of normal value for in vitro mitogen stimulation, or absent proliferation in vitro to antigen stimulation
- No available HLA identical related donor
- With severe infections, including but not limited to: pneumonitis; protracted diarrhea requiring total parenteral nutrition; infection with herpes viruses or adenovirus; disseminated BCG infection
- No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia
- No prior allogeneic stem cell transplantation
- Life expectancy ≥ 3 months
- Documented to be negative for HIV infection
- Written, informed consent obtained prior to any study-specific procedures
Who cannot take part
- Current treatment with any chemotherapeutic agent (becomes eligible if not on treatment for at least 1 month)
- Current treatment with any immunosuppressive agent, excluding corticosteroids
- Diagnosis of active malignant disease other than EBV-associated lymphoproliferative disease
- Patients with evidence of infection with HIV-1 or 2
- Presence of a medical condition indicating that survival will be less than 4 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical treatment
- No available molecular diagnosis confirming SCID-X1
- Existence of an available HLA-identical related donor
- Patients, in the opinion of investigators, may not be eligible or not able to comply with the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.
The group in the trial
- Single armTreatment being tested
In vivo LV gene transfer to treat SCID-X1
Treatment: Direct intravenous injection of ivlv-X1 lentiviral vector
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Via Direct Intravenous Injection of Lentiviral Vector (Ivlv-X1)
- Record updated
- 3 November 2026